27 June 2023 - Initial PET data on amyloid plaque reduction in Alzheimer's disease expected H1, 2024.
AC Immune today announced that it has received fast track designation from the US FDA for its wholly owned anti-amyloid beta active immunotherapy (vaccine) candidate, ACI-24.060, for treatment of Alzheimer’s disease.